Safety and efficacy of belatacept in heart transplantation

Active Cooperative Agreement Awarded Last action

Award ID
U01AI174997
Recipient
Awarding agency
Obligated
$12,692,538

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 71% complete
Place of performance
New York, NY 10016, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Although calcineurin inhibitors (CNIS), including tacrolimus have led to excellent 1-year outcomes in heart transplantation, long-term survival remains limited by cardiac allograft vasculopathy, driven by donor-specific-antibodies (DSA), and by CNI-associated morbidity, dominated by chronic kidney disease. Belatacept, a selective costimulation blocker, is FDA approved for use in kidney transplantation as a CNI- alternative. By inhibiting CD28/CD80/CD86 interactions belatacept prevents activation of both naïve T cell and T follicular helper cells associated with the development of DSA, but less effectively inhibits memory T cells. In kidney transplant recipients, this has translated to sustained improvement in kidney function, suppression of DSA, and improved graft/patient survival, albeit at the cost of more early rejection which has since been markedly reduced by using a delayed CNI substitution strategy. Building on these findings, we propose a randomized controlled trial of belatacept in first-time heart transplant recipients, in conjunction with gradual tacrolimus withdrawal over 9-MONTHS to achieve a CNI-free immunosuppressive regimen (with mycophenolate mofetil and prednisone). We hypothesize that the gradual approach to CNI withdrawal will promote quiescence in graft-reactive T cells, thereby preventing rejection, inhibiting the development of DSA, and eliminating CNI- related morbidity, together increasing survival after heart transplantation. The specific aims are: aim 1. Clinical trial to determine safety of belatacept in heart transplantation. We will perform a multicenter clinical trial in EBV seropositive heart transplant recipients randomized 2:1 to receive belatacept with gradual tacrolimus withdrawal (9-MONTHS) post-heart transplant or standard-of-care tacrolimus (CONTROL). The objectives are to a) establish safety of the protocol based on stopping criteria defined by the composite of historical CONTROL event rates and B) test efficacy for kidney sparing and DSA. Aim 2. Impact of CNI withdrawal under costimulation blockade on graft-reactive immune responses. We will serially analyze donor reactive, and autoantigen reactive T cell and B cell subsets using state-of-the-art phenotypic and functional assays and will quantify DSA and autoantibodies. Results will be compared between study arms and the kinetics of responses will be evaluated in individual subjects over time. Aim 3. Other mechanistic/biomarker studies relevant to primary and secondary endpoints in the trial. We will use molecular approaches to define differences in the intragraft response, explore markers of kidney injury and fibrosis, and test donor derived cell-free DNA as a potential biomarker of impeding rejection during CNI withdrawal. If successful, belatacept has the potential to transform the heart transplant field, removing CNI-morbidities and preventing DSA as major barriers to improving long-term survival. The comprehensive mechanistic studies will provide novel information, regardless of outcomes of the trial.

Transactions

Action Obligated Date
Amendment $0
Amendment $2,042,672
Amendment $2,042,672
Amendment $1,710,716
Amendment $1,672,806
Amendment $1,672,806
Amendment $1,775,433
Original award $1,775,433

Subawards

Subrecipient Amount Awarded
Cedars-Sinai Medical Center The goal is to a) minimize practice variability, b) standardize the factors influencing the decision to perform a for cause biopsy, and thus c) provide a highly… $173,376
The Cleveland Clinic Foundation $60,618
Cedars-Sinai Medical Center $95,173
The Massachusetts General Hospital $32,195
Cedars-Sinai Medical Center $168,600
Cedars-Sinai Medical Center $26,558
Cedars-Sinai Medical Center $93,687
University Of Pittsburgh - Of The Commonwealth System Of Higher Education $124,809
Icahn School Of Medicine At Mount Sinai $17,091
The Massachusetts General Hospital $32,037
Cedars-Sinai Medical Center This project aims to develop ethics guidelines for explaining NRP to organ donor family members, who are critical to the organ donation process. $217,518
The Massachusetts General Hospital The goal is to a) minimize practice variability, b) standardize the factors influencing the decision to perform a for cause biopsy, and thus c) provide a highly… $18,509
Icahn School Of Medicine At Mount Sinai $38,809
University Of Pittsburgh - Of The Commonwealth System Of Higher Education $130,092
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University $7,805
Show all 15

Quick answers

Who received award U01AI174997?

U01AI174997 was awarded to New York University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 6, 2023.

How much is award U01AI174997 worth?

$12,692,538 has been obligated on U01AI174997.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login